Extending outcomes for pancreas cancer patients with nominal oligometastatic disease (EXPAND): A randomized phase III trial

All Clinical Trials
Share on Facebook Share on X Share on LinkedIn Email

The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).